Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 1/20 | 0.67 |
| ▸ | APLNR | P35414 | 1/20 | 0.67 |
| ▸ | CCR6 | P51684 | 1/20 | 0.67 |
| ▸ | TOP1 | P11387 | 8/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.61 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.58 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.58 |
| ▸ | F3 | P13726 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | USP7 | Q93009 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19360128 | 1.00 | CXCR5 (0.67) | CXCR5APLNRCCR6TOP1PTPN1 | |
| SCHEMBL13559837 | 0.98 | TOP1 (0.66) | CXCR5APLNRCCR6TOP1PTPN1 | |
| SCHEMBL13007191 | 0.93 | PTPN1 (0.70) | CXCR5APLNRCCR6TOP1PTPN1 | |
| SCHEMBL29934271 | 0.93 | TOP1 (0.61) | CXCR5APLNRCCR6TOP1PTPN1 | |
| SCHEMBL23584144 | 0.92 | CXCR5 (0.61) | CXCR5APLNRCCR6TOP1PTPN1 | |
| SCHEMBL13867747 | 0.92 | TOP1 (0.65) | CXCR5APLNRCCR6TOP1PTPN1 | |
| SCHEMBL19978662 | 0.91 | CXCR5 (0.60) | CXCR5APLNRCCR6TOP1PTPN1 | |
| SCHEMBL13007183 | 0.91 | PTPN1 (0.68) | CXCR5APLNRCCR6TOP1PTPN1 | |
| SCHEMBL15393753 | 0.90 | TOP1 (0.62) | CXCR5APLNRCCR6TOP1PTPN1 | |
| SCHEMBL9061363 | 0.90 | TOP1 (0.58) | CXCR5APLNRCCR6TOP1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340012-A1 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | PACIFIC ARROW LTD (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230159436-A1 | APPLICATIONS OF AMIDE ANALOGS OF TRITERPENES IN CURES OF CANCER AND OTHER DISEASES | PACIFIC ARROW LTD (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159436-A1 | APPLICATIONS OF AMIDE ANALOGS OF TRITERPENES IN CURES OF CANCER AND OTHER DISEASES | PACIFIC ARROW LTD (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-3301105-A1 | NEW COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | Pacific Arrow Limited (VG) | 2018-04-04 | — | — | EP | disclosed |
| US-20170022246-A1 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | PACIFIC ARROW LTD (CN) | 2017-01-26 | — | — | US | disclosed |
| US-20160354397-A1 | METHODS AND COMPOUNDS FOR MODULATING THE SECRETION OR EXPRESSION OF ADHESION PROTEINS OR ANGIOPOIETINS OF CELLS | PACIFIC ARROW LTD (CN) | 2016-12-08 | — | — | US | disclosed |
| US-9499577-B2 | Natural and synthetic compounds for treating cancer and other diseases | PACIFIC ARROW LTD (CN) | 2016-11-22 | — | — | US | disclosed |
| US-9434677-B2 | Natural and synthetic compounds for treating cancer and other diseases | PACIFIC ARROW LIMITED (HK) | 2016-09-06 | — | — | US | disclosed |
| US-9382285-B2 | Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells | PACIFIC ARROW LIMITED (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20140322810-A1 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | PACIFIC ARROW LTD (CN) | 2014-10-30 | — | — | US | disclosed |
| US-8785405-B2 | Compounds for treating cancer and other diseases | PACIFIC ARROW LIMITED (CN) | 2014-07-22 | — | — | US | disclosed |
| US-20140199378-A1 | NEW NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | PACIFIC ARROW LIMITED (CN) | 2014-07-17 | — | — | US | disclosed |
| US-20140024113-A1 | COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | PACIFIC ARROW LIMITED (CN) | 2014-01-23 | — | — | US | disclosed |
| US-8586719-B2 | Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents | PACIFIC ARROW LIMITED (CN) | 2013-11-19 | — | — | US | disclosed |
| US-20120277308-A1 | COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | PACIFIC ARROW LIMITED (CN) | 2012-11-01 | — | — | US | disclosed |
| WO-2011009032-A1 | INHIBITING THE INVASION AND METASTASIS OF CANCER CELLS | PACIFIC ARROW LIMITED (CN) | 2011-01-20 | — | — | WO | disclosed |
| US-20100317606-A1 | NOVEL TRITERPENES FOR MODULATING GENE EXPRESSION AND CELL MEMBRANE, AND AS ANTIPROTOZOAL AGENTS | PACIFIC ARROW LIMITED (CN) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024113-A1 | COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | TEK, VCAM1, EPCAM | CXCR5 310/4885APLNR 49/4885CCR6 304/4885 |
| US-20170022246-A1 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | VCAM1, EPCAM, ICAM1 | CXCR5 667/4885APLNR 10/4885CCR6 710/4885 |
| US-20230340012-A1 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | TEK, VCAM1, MCL1 | CXCR5 382/4885APLNR 81/4885CCR6 449/4885 |
| US-20100317606-A1 | NOVEL TRITERPENES FOR MODULATING GENE EXPRESSION AND CELL MEMBRANE, AND AS ANTIPROTOZOAL AGENTS | TEK, PTK2, MPL | CXCR5 1487/4885APLNR 429/4885CCR6 267/4885 |
| US-20120277308-A1 | COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | TEK, VCAM1, EPCAM | CXCR5 310/4885APLNR 49/4885CCR6 304/4885 |
| US-20230159436-A1 | APPLICATIONS OF AMIDE ANALOGS OF TRITERPENES IN CURES OF CANCER AND OTHER DISEASES | UACA, BRDT, FLT3 | CXCR5 1808/4885APLNR 1479/4885CCR6 3008/4885 |
| US-20160354397-A1 | METHODS AND COMPOUNDS FOR MODULATING THE SECRETION OR EXPRESSION OF ADHESION PROTEINS OR ANGIOPOIETINS OF CELLS | TEK, FN1, MYL6 | CXCR5 1259/4885APLNR 266/4885CCR6 189/4885 |
| US-20140322810-A1 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | VCAM1, EPCAM, ICAM1 | CXCR5 667/4885APLNR 10/4885CCR6 710/4885 |
| US-20140199378-A1 | NEW NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | VCAM1, EPCAM, TEK | CXCR5 594/4885APLNR 11/4885CCR6 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.